Roivant and its subsidiary Priovant have reported positive results from two Phase 3 studies of their drug Lisraya for non-infectious uveitis. The studies focused on an inflammatory eye disease that can lead to vision loss. Lisraya has recently received approval to treat dermatomyositis, a different inflammatory condition. Roivant stated that it intends to seek an expanded FDA approval for Lisraya in the first half of 2027. In separate news, Mark Cuban’s Cost Plus Drugs, an online pharmacy that aims to lower drug costs by bypassing middlemen, is expanding its operations. The company has primarily sold generic drugs but is now entering the field of experimental rare disease therapies.